Analytical Data
-
Gene name
viaA
- Application
-
Alternative Names
viaA；VGAT；VIAAT；Vesicular inhibitory amino acid transporter
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0ADN0
-
Expression Region
1-483aa
-
AA Sequence
MLTLDTLNVM LAVSEEGLIE EMIIALLASP QLAVFFEKFP RLKAAITDDV PRWREALRSR LKDARVPPEL TEEVMCYQQS QLLSTPQFIV QLPQILDLLH RLNSPWAEQA RQLVDANSTI TSALHTLFLQ RWRLSLIVQA TTLNQQLLEE EREQLLSEVQ ERMTLSGQLE PILADNNTAA GRLWDMSAGQ LKRGDYQLIV KYGEFLNEQP ELKRLAEQLG RSREAKSIPR NDAQMETFRT MVREPATVPE QVDGLQQSDD ILRLLPPELA TLGITELEYE FYRRLVEKQL LTYRLHGESW REKVIERPVV HKDYDEQPRG PFIVCVDTSG SMGGFNEQCA KAFCLALMRI ALAENRRCYI MLFSTEIVRY ELSGPQGIEQ AIRFLSQQFR GGTDLASCFR AIMERLQSRE WFDADAVVIS DFIAQRLPDD VTSKVKELQR VHQHRFHAVA MSAHGKPGIM RIFDHIWRFD TGMRSRLLRR WRR
-
Molecular Weight
55.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of viaA recombinant protein is driven by its potential implications in microbiology and vaccine development. viaA, a gene found in various pathogenic bacteria, plays a critical role in the virulence and pathogenicity of these organisms. Research has shown that viaA is involved in the synthesis of the polysaccharide capsule, which is essential for bacterial survival and immune evasion in hostile environments. Understanding the structure and function of viaA can provide insights into the mechanisms by which these pathogens evade host immune responses. Additionally, recombinant forms of viaA protein are being explored as candidates for generating specific antibodies and developing vaccines aimed at preventing infections caused by bacteria that express this gene. The ability to produce viaA protein in a laboratory setting allows for detailed studies on its immunogenic properties and the determination of its potential role in inducing protective immune responses. As antibiotic resistance becomes an increasing global health challenge, researching novel vaccine targets like viaA not only opens new avenues for intervention but also emphasizes the urgency of developing effective vaccines to combat bacterial infections. This research is essential for understanding bacterial pathogenesis and for advancing public health strategies in the fight against infectious diseases.
